Treatment Response in Patients With Medication-Overuse Headache
Factors Affecting Treatment Response in Patients With Medication-Overuse Headache Undergoing Greater Occipital Nerve Blockade
Sultan 1. Murat State Hospital
70 participants
Mar 17, 2026
OBSERVATIONAL
Conditions
Summary
The aim of this study to evaluate pre-injection patient-related factors that may influence treatment response in patients with medication-overuse headache who underwent ultrasound-guided greater occipital nerve block.
Eligibility
Inclusion Criteria4
- Age between 18 and 65 years
- Diagnosis of medication-overuse headache according to the International Classification of Headache Disorders, 3rd edition (ICHD-3)
- Diagnosis of medication-overuse headache associated with the use of triptans or nonsteroidal anti-inflammatory drugs
- Previous diagnosis of chronic migraine or chronic tension-type headache according to the ICHD-3 criteria
Exclusion Criteria9
- History of severe head or neck trauma or previous neurosurgical intervention
- Presence of a severe psychiatric disorder (e.g., severe depression, schizophrenia)
- History of infectious disease, chronic inflammatory disease, or malignancy
- Previous diagnosis of secondary headache
- History of substance abuse
- Pregnancy or breastfeeding
- History of an additional neurological disorder (e.g., cerebrovascular disease, multiple sclerosis)
- Difficulty with cooperation
- Presence of a concomitant systemic disease that may affect quality of life (e.g., congestive heart failure, chronic kidney disease, chronic liver disease, pulmonary disease, uncontrolled diabetes, or peripheral vascular disease)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Before the injection, patients will be evaluated for the number of headache days, headache severity, the number of days of analgesic use for headache, headache-related disability, pressure pain threshold over the bilateral greater occipital nerve, anxiety and depression scores, and sleep quality. At 1 and 2 months after the injection, they will be reassessed for the number of headache days, headache severity, and the number of days of analgesic use for headache. In addition, at 1 hour after the injection, the pain experienced during the injection procedure will be assessed.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07487649